A resolution expressing the sense of the Senate that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Equitable Access to Care: The resolution states that preserving and expanding access to medication abortion, including through telemedicine and mail-sourcing, is important to address reproductive health disparities faced by various groups, including Black and Indigenous people, people of color, immigrants, people with lower incomes, people in rural communities, LGBTQ+ people, people living with disabilities, and people experiencing intimate partner violence. (Section 4)

Reduced Burdens on Patient Access: The text notes that the FDA modified the Mifepristone REMS in January 2023 to remove the in-person dispensing requirement, which helps lessen burdens on patient access and the health care system. (Whereas clauses)

Increased Privacy and Safety for Vulnerable Patients: The resolution mentions that the privacy provided by a telehealth consultation may increase a patient's willingness to disclose abuse or coercion. (Whereas clauses)

Devastating Health Impacts from Reduced Access: The text states that the impact to the health and well-being of patients across the country would be devastating if any action reduced patient access to medication abortion or increased barriers to prescribing and dispensing it. (Whereas clauses)

Increased Physical and Financial Burdens: The resolution notes that abortion bans and restrictions force patients to travel greater distances for care and face longer wait times. (Whereas clauses)